speb/financial-data huggingface dataset:
Financial ratios for CMIG4.SA — quarterly report dated 2024-12-31
Total revenue: 2193429935.275081
Gross profit: -217078964.4012945
Operating income: -32916343.042071197
Net income: 161379611.65048546
Capital expenditures: 547920064.7249191
Operating cash flow: -333782362.4595469
Depreciation & amortization: -49102265.37216829
Net tangible assets: 1710517799.3527508
Owner earnings: -435642718.4466019
Return on net tangible assets (%): -25.468470343392298
Buffett classification: The Gruesome
Stock price: 1.4523424878836833
P/E ratio: 4.283961906790324
Shares outstanding: 1904080104
Book value: 4430744336.56958
P/B ratio: 0.6241336049450831
Market cap (USD): 2765376435.3731823
Debt to equity: 0.4641370243225476
Current ratio: 0.864696734059098
Quick ratio: 0.864696734059098
Effective tax rate (%): 13.632809151063736
Interest coverage ratio: -0.7351991933239606
COGS to revenue (%): 79.21883069894595
SG&A to revenue (%): 0.9239640860389408
Free cash flow (dilution-adjusted): 192812944.98381877
Buyback yield (%): 0
Receivables turnover: 1.840515546503734
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.4462890239354116
FCF margin (%): 8.790476590246673
Revenue growth (%): -4.813572363220476
Rule of 40 score: 3.976904227026197
Financial ratios for CMIG4.SA — annual report dated 2024-12-31
Total revenue: 8013754045.307444
Gross profit: 1266990291.262136
Operating income: 1285275080.906149
Net income: 1151941747.5728157
Capital expenditures: 92233009.70873787
Operating cash flow: 889320388.3495146
Depreciation & amortization: 222653721.68284792
Net tangible assets: 1710517799.3527508
Owner earnings: 1282362459.5469258
Return on net tangible assets (%): 74.96925551035855
Capex to operating income (%): 7.17612992572076
Buffett classification: The Great
Stock price: 1.4523424878836833
P/E ratio: 2.400621768591974
Shares outstanding: 1904080104
Book value: 4430744336.56958
P/B ratio: 0.6241336049450831
Market cap (USD): 2765376435.3731823
Debt to equity: 0.4641370243225476
Current ratio: 0.864696734059098
Quick ratio: 0.864696734059098
Effective tax rate (%): 23.926052575336612
Interest coverage ratio: 8.031344792719919
COGS to revenue (%): 64.59363957597174
SG&A to revenue (%): 2.544169611307421
Free cash flow (dilution-adjusted): 740614886.7313917
Buyback yield (%): 0
Receivables turnover: 6.724372029871011
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 17.426120532678087
FCF margin (%): 9.241797072185767
Revenue growth (%): -14.57866567089868
Rule of 40 score: -5.336868598712913
Financial ratios for CMIG4.SA — quarterly report dated 2025-03-31
Total revenue: 2059641515.6128473
Gross profit: 232197425.4097222
Operating income: 24196954369.854164
Net income: 180381944.44444445
Capital expenditures: 305902777.7777778
Operating cash flow: 238194444.44444445
Depreciation & amortization: 63194444.44444445
Net tangible assets: 1879861111.1111112
Owner earnings: -62326388.888888896
Return on net tangible assets (%): -3.3154783893609165
Capex to operating income (%): 1.2642201704479283
Buffett classification: The Great
Stock price: 1.4687500000000002
P/E ratio: 3.875966717959577
Shares outstanding: 1904080104
Book value: 4847395833.333334
P/B ratio: 0.576931975210057
Market cap (USD): 2796617652.7500005
Debt to equity: 0.5608681637477168
Current ratio: 1.0595083202081763
Quick ratio: 1.0595083202081763
Effective tax rate (%): 14.41515650741351
Interest coverage ratio: 314.6150274725959
COGS to revenue (%): 67.46724237202328
SG&A to revenue (%): 1.6352629960235527
Free cash flow (dilution-adjusted): -67708333.33333334
Buyback yield (%): 0
Retained earnings: 86805555.55555555
Receivables turnover: 1.6167259648310166
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 282.71254421055187
FCF margin (%): -3.2873843734494104
Revenue growth (%): -6.0995073291664195
Rule of 40 score: -9.38689170261583
Financial ratios for CMIG4.SA — quarterly report dated 2025-06-30
Operating income: 278621532.84671533
Capital expenditures: 0
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 1.7627737226277371
P/E ratio: 3.548622400295106
Shares outstanding: 1904080104
Market cap (USD): 3356462373.109489
Interest coverage ratio: 3.9196028145946133
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CMIG4.SA — quarterly report dated 2025-09-30
Total revenue: 2438854511.2781954
Gross profit: 283565601.5037594
Operating income: 192459210.52631578
Net income: 149763533.83458647
Capital expenditures: 830827067.6691729
Operating cash flow: 643609022.556391
Depreciation & amortization: 208646616.54135337
Net tangible assets: 2012781954.887218
Owner earnings: -472416917.29323304
Return on net tangible assets (%): -23.47084422861412
Capex to operating income (%): 431.6899489492452
Buffett classification: The Gruesome
Stock price: 1.9097744360902256
P/E ratio: 7.398123882971395
Shares outstanding: 1904080104
Book value: 5401127819.548872
P/B ratio: 0.6732600353810817
Market cap (USD): 3636363506.887218
Debt to equity: 0.5511241038490986
Current ratio: 0.890016124697662
Quick ratio: 0.890016124697662
Effective tax rate (%): 5.881310622553983
Interest coverage ratio: 2.420527186761229
COGS to revenue (%): 69.5130664232392
SG&A to revenue (%): 1.5054907602530647
Free cash flow (dilution-adjusted): -187218045.11278194
Buyback yield (%): 0
Retained earnings: 242293233.08270675
Receivables turnover: 1.713511093502377
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.0532687602775437
FCF margin (%): -7.676474518960198
Rule of 40 score: -7.676474518960198
Financial ratios for CMIG4.SA — annual report dated 2025-12-31
Total revenue: 9513686131.38686
Gross profit: 1320620437.9562042
Operating income: 1154744525.547445
Net income: 893978102.189781
Capital expenditures: 110583941.6058394
Operating cash flow: 743978102.189781
Depreciation & amortization: 279744525.54744524
Net tangible assets: 1830109489.0510948
Owner earnings: 1063138686.1313869
Return on net tangible assets (%): 58.091534549805566
Capex to operating income (%): 9.576485461441214
Buffett classification: The Great
Stock price: 1.8976660682226212
P/E ratio: 4.04183077380517
Shares outstanding: 1904080104
Book value: 5215510948.905109
P/B ratio: 0.6928004254879649
Market cap (USD): 3613308204.5385995
Debt to equity: 0.6956719498967845
Current ratio: 1.0011063476697553
Quick ratio: 1.0011063476697553
Effective tax rate (%): 13.597883597883598
Interest coverage ratio: 4.210246174318031
COGS to revenue (%): 68.1193056487964
SG&A to revenue (%): 0.23784405869377578
Free cash flow (dilution-adjusted): 547262773.7226276
Buyback yield (%): 0
Receivables turnover: 6.543047188755019
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 12.038199596697483
FCF margin (%): 5.752373645343819
Revenue growth (%): 18.71697181619544
Rule of 40 score: 24.46934546153926
Financial ratios for CMIG4.SA — quarterly report dated 2025-12-31
Total revenue: 2582689598.540146
Gross profit: 317086131.38686126
Operating income: 435754927.00729924
Net income: 342196532.84671533
Capital expenditures: 752049087.5912408
Operating cash flow: -308972810.2189781
Depreciation & amortization: -56430656.93430656
Net tangible assets: 1830109489.0510948
Owner earnings: -466283211.678832
Return on net tangible assets (%): -25.4784325456177
Capex to operating income (%): 172.5853320250911
Buffett classification: The Gruesome
Stock price: 1.8976660682226212
P/E ratio: 5.374211554159172
Shares outstanding: 1904080104
Book value: 5215510948.905109
P/B ratio: 0.6928004254879649
Market cap (USD): 3613308204.5385995
Debt to equity: 0.6956719498967845
Current ratio: 1.0011063476697553
Quick ratio: 1.0011063476697553
Effective tax rate (%): 15.96951086993052
Interest coverage ratio: 5.6269104430484145
COGS to revenue (%): 69.6323055966595
SG&A to revenue (%): -4.836142710108337
Free cash flow (dilution-adjusted): 369810766.4233576
Buyback yield (%): 0
Receivables turnover: 1.7762473644578314
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.5427405547311945
FCF margin (%): 14.31882354861349
Revenue growth (%): 5.8976493512344454
Rule of 40 score: 20.216472899847936
Financial ratios for COA.L — annual report dated 2021-12-31
Capital expenditures: 0
Depreciation & amortization: 4459459.459459459
Buffett classification: The Gruesome
Stock price: 0.008243243243243242
Shares outstanding: 1914361942
Market cap (USD): 15780551.143513512
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for COA.L — annual report dated 2022-12-31
Total revenue: 1852530120.4819279
Gross profit: 576385542.1686747
Operating income: 265301204.8192771
Net income: 8795180.722891567
Capital expenditures: 37228915.66265061
Operating cash flow: 116144578.31325302
Depreciation & amortization: 69397590.36144578
Net tangible assets: 3734939.7590361447
Owner earnings: 40963855.421686746
Return on net tangible assets (%): 1096.774193548387
Capex to operating income (%): 14.032697547683926
Buffett classification: The Great
Stock price: 0.007228915662650603
P/E ratio: 1.5734481715068491
Shares outstanding: 1914361942
Book value: 783855421.6867471
P/B ratio: 0.017654736630802335
Market cap (USD): 13838761.026506025
Debt to equity: 1.0332001229634185
Current ratio: 1.7452609711763178
Quick ratio: 1.196312646065957
Effective tax rate (%): 37.25231175693527
Interest coverage ratio: 6.592814371257484
COGS to revenue (%): 68.88657648283039
SG&A to revenue (%): 16.87044745057232
Free cash flow (dilution-adjusted): 75542168.6746988
Buyback yield (%): 18.282854058117294
Retained earnings: 261084337.3493976
Inventory turnover: 5.010406811731316
Receivables turnover: 6.529087048832271
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 14.64387843319811
FCF margin (%): 4.077783558792924
Rule of 40 score: 4.077783558792924
Financial ratios for COA.L — annual report dated 2023-12-31
Total revenue: 1764810126.5822785
Gross profit: 588734177.2151898
Operating income: 276455696.20253164
Net income: 93797468.35443038
Capital expenditures: 24303797.46835443
Operating cash flow: 156835443.0379747
Depreciation & amortization: 86962025.31645569
Net tangible assets: -48987341.772151895
Owner earnings: 156455696.20253164
Return on net tangible assets (%): -319.3798449612403
Capex to operating income (%): 8.791208791208792
Buffett classification: The Great
Stock price: 0.00911392405063291
P/E ratio: 0.18601087695546556
Shares outstanding: 1914361942
Book value: 746075949.3670886
P/B ratio: 0.023385486906006104
Market cap (USD): 17447349.344810124
Debt to equity: 1.023583305055989
Current ratio: 1.158148505303761
Quick ratio: 0.823529411764706
Effective tax rate (%): 35.30166880616175
Interest coverage ratio: 5.702349869451697
COGS to revenue (%): 66.64036723569072
SG&A to revenue (%): 18.11074451298235
Free cash flow (dilution-adjusted): 117594936.70886075
Buyback yield (%): 73.27651824880344
Retained earnings: 199240506.3291139
Inventory turnover: 5.355043227665706
Receivables turnover: 5.855522889542209
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 18.263923733065727
FCF margin (%): 6.663319466360637
Revenue growth (%): -4.735145352283363
Rule of 40 score: 1.9281741140772741
Financial ratios for COA.L — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: -272250000
Buffett classification: The Gruesome
Stock price: 0.011250000000000001
Shares outstanding: 1914361942
Book value: 473250000
P/B ratio: 0.045507811616481784
Market cap (USD): 21536571.847500004
Debt to equity: 1.7921288959323824
Current ratio: 1.541385346336584
Quick ratio: 1.1010252563140785
Buyback yield (%): 0
Retained earnings: -44250000
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for COA.L — annual report dated 2024-12-31
Total revenue: 1791250000
Gross profit: 660000000
Operating income: 316500000
Net income: 124625000
Capital expenditures: 28375000
Operating cash flow: 119750000
Depreciation & amortization: 80250000
Net tangible assets: -272250000
Owner earnings: 176500000
Return on net tangible assets (%): -64.83011937557393
Capex to operating income (%): 8.9652448657188
Buffett classification: The Great
Stock price: 0.011250000000000001
P/E ratio: 0.17281100780341024
Shares outstanding: 1914361942
Book value: 473250000
P/B ratio: 0.045507811616481784
Market cap (USD): 21536571.847500004
Debt to equity: 1.7921288959323824
Current ratio: 1.541385346336584
Quick ratio: 1.1010252563140785
Effective tax rate (%): 36.11111111111111
Interest coverage ratio: 7.172804532577904
COGS to revenue (%): 63.15422191207257
SG&A to revenue (%): 19.176552686671318
Free cash flow (dilution-adjusted): 87625000
Buyback yield (%): 50.49550168432394
Retained earnings: -44250000
Inventory turnover: 5.139125496876774
Receivables turnover: 5.832315832315833
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 20.911793855302278
FCF margin (%): 4.891835310537334
Revenue growth (%): 1.4981709941184904
Rule of 40 score: 6.390006304655825
Financial ratios for COA.L — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: -265068493.15068495
Buffett classification: The Gruesome
Stock price: 0.010547945205479452
Shares outstanding: 1914361942
Book value: 563698630.136986
P/B ratio: 0.03582159648456867
Market cap (USD): 20192584.867671233
Debt to equity: 1.6274605103280688
Current ratio: 1.6214964660004874
Quick ratio: 1.193029490616622
Buyback yield (%): 0
Retained earnings: -35479452.05479452
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CONCORDBIO.NS — annual report dated 2024-03-31
Total revenue: 119685489.86689052
Gross profit: 90711991.84554502
Operating income: 46322424.751169205
Net income: 36947259.86329296
Capital expenditures: 10254634.848303154
Operating cash flow: 31834404.604868688
Depreciation & amortization: 6426609.90526442
Net tangible assets: 183034632.44993404
Owner earnings: 33119234.92025423
Return on net tangible assets (%): 18.09451822147015
Capex to operating income (%): 22.13751741923726
Buffett classification: The Great
Stock price: 18.027231285988485
P/E ratio: 51.0441237793613
Shares outstanding: 104616204
Book value: 183072970.3801415
P/B ratio: 10.301578118572591
Market cap (USD): 1885940505.7701538
Debt to equity: 0.006378429045904895
Current ratio: 6.304587092716844
Quick ratio: 4.841724619676776
Effective tax rate (%): 25.320082896028506
Interest coverage ratio: 151.37062580822132
COGS to revenue (%): 24.208028937817495
SG&A to revenue (%): 4.432440902942146
Free cash flow (dilution-adjusted): 21558772.03501619
Buyback yield (%): 0
Retained earnings: 168484830.31538555
Inventory turnover: 1.16184460202218
Receivables turnover: 2.854782301022657
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 24.784699347105978
FCF margin (%): 18.012853570631666
Revenue growth (%): 18.2975896921852
Rule of 40 score: 36.31044326281686
Financial ratios for CONCORDBIO.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 189870473.0052556
Buffett classification: The Gruesome
Stock price: 24.124104156712853
Shares outstanding: 104616204
Book value: 189964070.7118968
P/B ratio: 13.285523901009268
Market cap (USD): 2523772201.77592
Debt to equity: 0.00215269414992349
Current ratio: 6.595407888924486
Quick ratio: 4.82827850169992
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CONCORDBIO.NS — quarterly report dated 2024-12-31
Total revenue: 28467210.630609628
Gross profit: 22359505.76990325
Operating income: 9871546.800326377
Net income: 8849644.480708707
Capital expenditures: 0
Depreciation & amortization: 1546100.9441659865
Owner earnings: 10395745.424874693
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 25.606014687026455
P/E ratio: 75.67547097412971
Shares outstanding: 104616204
Market cap (USD): 2678804056.1249557
Effective tax rate (%): 24.943772904817788
Interest coverage ratio: 869.4866529774126
COGS to revenue (%): 21.455227700247566
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for CONCORDBIO.NS — annual report dated 2025-03-31
Total revenue: 137925859.24713582
Gross profit: 100784685.52723871
Operating income: 54167278.466214634
Net income: 43446609.77320551
Capital expenditures: 12973252.279635258
Operating cash flow: 28585094.6925415
Depreciation & amortization: 6356499.883095628
Net tangible assets: 211783422.9600187
Owner earnings: 36829857.37666588
Return on net tangible assets (%): 17.390340028463307
Capex to operating income (%): 23.950349079706804
Buffett classification: The Great
Stock price: 19.488271676975145
P/E ratio: 46.9263083128576
Shares outstanding: 104616204
Book value: 211914601.3560907
P/B ratio: 9.620804759649266
Market cap (USD): 2038789005.365854
Debt to equity: 0.0016380379182084357
Current ratio: 6.167696207703249
Quick ratio: 4.865600073018636
Effective tax rate (%): 24.852932939685164
Interest coverage ratio: 875.3956168524467
COGS to revenue (%): 26.928361311382147
SG&A to revenue (%): 4.020781852926783
Free cash flow (dilution-adjusted): 15588578.44283376
Buyback yield (%): 0
Retained earnings: 197693126.02291325
Inventory turnover: 1.3256115146336254
Receivables turnover: 2.2616973209125244
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 25.04322126243434
FCF margin (%): 11.30214343265545
Revenue growth (%): 15.24025126231385
Rule of 40 score: 26.5423946949693
Financial ratios for CONCORDBIO.NS — quarterly report dated 2025-03-31
Total revenue: 50255295.76806172
Gross profit: 35233376.198269814
Operating income: 20552501.753565583
Net income: 16411877.484217908
Capital expenditures: 0
Depreciation & amortization: 1708744.4470423192
Net tangible assets: 211783422.9600187
Owner earnings: 18120621.93126023
Return on net tangible assets (%): 8.556204106060326
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 19.488271676975145
P/E ratio: 31.056608351579623
Shares outstanding: 104616204
Book value: 211914601.3560907
P/B ratio: 9.620804759649266
Market cap (USD): 2038789005.365854
Debt to equity: 0.0016380379182084357
Current ratio: 6.167696207703249
Quick ratio: 4.865600073018636
Effective tax rate (%): 23.513137435015654
Interest coverage ratio: 1840.9015706806283
COGS to revenue (%): 29.891217114950603
Buyback yield (%): 0
Retained earnings: 197693126.02291325
Inventory turnover: 0.5361497109324931
Receivables turnover: 0.8240823614999668
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 9.502062194838594
Revenue growth (%): 76.5374782242425
Rule of 40 score: 76.5374782242425
Financial ratios for CONCORDBIO.NS — quarterly report dated 2025-06-30
Total revenue: 23869365.78516265
Gross profit: 18591551.603089165
Operating income: 5104317.809501521
Net income: 5155370.933770185
Capital expenditures: 0
Depreciation & amortization: 2080072.5485607304
Owner earnings: 7235443.4823309155
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 21.389421951790315
P/E ratio: 73.56701875510913
Shares outstanding: 104616204
Market cap (USD): 2237680130.3505735
Effective tax rate (%): 24.98476123667247
Interest coverage ratio: 744.3941979522184
COGS to revenue (%): 22.111245977696683
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -52.50378010841968
Rule of 40 score: -52.50378010841968
Financial ratios for CONCORDBIO.NS — quarterly report dated 2025-09-30
Total revenue: 27853156.70800451
Gross profit: 22327080.045095827
Operating income: 7902998.8726042835
Net income: 7109673.055242389
Capital expenditures: 0
Depreciation & amortization: 2073449.8308906425
Net tangible assets: 205804351.74746335
Owner earnings: 9183122.886133032
Return on net tangible assets (%): 4.462064484137527
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 18.576099210823
P/E ratio: 51.786272875301606
Shares outstanding: 104616204
Book value: 205953821.8714769
P/B ratio: 9.435906393504219
Market cap (USD): 1943360984.5636978
Debt to equity: 0.0008794563464276314
Current ratio: 6.967527841942935
Quick ratio: 5.184886631995973
Effective tax rate (%): 26.400728257317585
Interest coverage ratio: 1186.1184433164128
COGS to revenue (%): 19.84003723829473
Buyback yield (%): 0
Inventory turnover: 0.17741703715795687
Receivables turnover: 0.6226421656452588
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.7521799969018916
Revenue growth (%): 16.689973913417543
Rule of 40 score: 16.689973913417543
Financial ratios for CONCORDBIO.NS — quarterly report dated 2025-12-31
Total revenue: 30941962.793806396
Gross profit: 23619382.867327616
Operating income: 8937674.055920687
Net income: 7089395.120864431
Capital expenditures: 0
Depreciation & amortization: 2088325.7212877355
Owner earnings: 9177720.842152167
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 14.989417400022278
P/E ratio: 43.843931885923716
Shares outstanding: 104616204
Market cap (USD): 1568135948.5618804
Effective tax rate (%): 26.132162742191774
Interest coverage ratio: 984.4601226993866
COGS to revenue (%): 23.665531418532147
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 11.089608686667173
Rule of 40 score: 11.089608686667173
Financial ratios for DIOD — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 109.81
Shares outstanding: 45944734
Market cap (USD): 5045191240.54
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DIOD — annual report dated 2022-12-31
Total revenue: 2000580000
Gross profit: 827237000
Operating income: 404542000
Net income: 339255000
Capital expenditures: 211310000
Operating cash flow: 392501000
Depreciation & amortization: 127759000
Net tangible assets: 1289751000
Owner earnings: 255704000
Return on net tangible assets (%): 19.82584235251611
Capex to operating income (%): 52.23437863064898
Buffett classification: The Good
Stock price: 76.14
P/E ratio: 10.311512127337842
Shares outstanding: 45944734
Book value: 1582919000
P/B ratio: 2.209988032716772
Market cap (USD): 3498232046.76
Debt to equity: 0.13498732405132544
Current ratio: 2.6857582133031235
Quick ratio: 1.852796337826278
Effective tax rate (%): 14.316563115623579
Interest coverage ratio: 48.62283653846154
COGS to revenue (%): 58.650141458976904
R&D to revenue (%): 6.3139689490047886
SG&A to revenue (%): 14.03977846424537
Free cash flow (dilution-adjusted): 144486000
Buyback yield (%): 0
Retained earnings: 1448092000
Inventory turnover: 3.2567440414565296
Receivables turnover: 5.418204765012878
Capitalized R&D asset: 126316000
ROCI (R&D-adjusted, %): 24.65835022620812
FCF margin (%): 7.222205560387487
Rule of 40 score: 7.222205560387487
Financial ratios for DIOD — annual report dated 2023-12-31
Total revenue: 1661739000
Gross profit: 658182000
Operating income: 250109000
Net income: 230648000
Capital expenditures: 148000000
Operating cash flow: 280914000
Depreciation & amortization: 137330000
Net tangible assets: 1530246000
Owner earnings: 219978000
Return on net tangible assets (%): 14.375335730333555
Capex to operating income (%): 59.17420004877874
Buffett classification: The Good
Stock price: 80.52
P/E ratio: 16.039462651659672
Shares outstanding: 45944734
Book value: 1809677000
P/B ratio: 2.0442708735757815
Market cap (USD): 3699469981.68
Debt to equity: 0.054351135589389706
Current ratio: 3.017512160163457
Quick ratio: 2.026975994795399
Effective tax rate (%): 17.01309308358489
Interest coverage ratio: 43.87877192982456
COGS to revenue (%): 60.39197491302786
R&D to revenue (%): 8.11607599027284
SG&A to revenue (%): 15.522233034188885
Free cash flow (dilution-adjusted): 99234000
Buyback yield (%): 0
Retained earnings: 1675274000
Inventory turnover: 2.5747150913093226
Receivables turnover: 4.467881052886296
Capitalized R&D asset: 219499720
ROCI (R&D-adjusted, %): 13.580754031401296
Rosenberg metric: -1.3383498527502453
FCF margin (%): 5.971695916145676
Revenue growth (%): -16.937138229913327
Rule of 40 score: -10.96544231376765
Financial ratios for DIOD — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 64.09
Shares outstanding: 45944734
Market cap (USD): 2944598002.06
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DIOD — annual report dated 2024-12-31
Total revenue: 1311120000
Gross profit: 435862000
Operating income: 51400000
Net income: 50842000
Capital expenditures: 72208000
Operating cash flow: 119435000
Depreciation & amortization: 137136000
Net tangible assets: 1546349000
Owner earnings: 115770000
Return on net tangible assets (%): 7.486666981386479
Capex to operating income (%): 140.48249027237352
Buffett classification: The Gruesome
Stock price: 61.67
P/E ratio: 55.72974599307659
Shares outstanding: 45944734
Book value: 1868947000
P/B ratio: 1.5160471355153464
Market cap (USD): 2833411745.78
Debt to equity: 0.049066131891380545
Current ratio: 3.259228000298193
Quick ratio: 1.994709741317799
Effective tax rate (%): 18.8889952458441
Interest coverage ratio: 22.022279348757497
COGS to revenue (%): 66.75651351516261
R&D to revenue (%): 10.224159497223747
SG&A to revenue (%): 17.840701079992677
Free cash flow (dilution-adjusted): 23644000
Buyback yield (%): 0
Retained earnings: 1719298000
Inventory turnover: 1.8428501646496038
Receivables turnover: 4.02780807146785
Capitalized R&D asset: 266096840
ROCI (R&D-adjusted, %): 2.3588557786458804
Rosenberg metric: -1.6484266097220985
FCF margin (%): 1.8033437061443651
Revenue growth (%): -21.09952284925611
Rule of 40 score: -19.296179143111747
Financial ratios for DIOD — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 61.67
Shares outstanding: 45944734
Market cap (USD): 2833411745.78
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for DIOD — quarterly report dated 2025-03-31
Total revenue: 332113000
Gross profit: 104694000
Operating income: 1278000
Net income: -2787000
Capital expenditures: 15836000
Operating cash flow: 56743000
Depreciation & amortization: 35904000
Net tangible assets: 1557361000
Owner earnings: 17281000
Capex to operating income (%): 1239.1236306729265
Buffett classification: The Gruesome
Stock price: 43.17
Shares outstanding: 45944734
Book value: 1871834000
P/B ratio: 1.05962076059095
Market cap (USD): 1983434166.78
Debt to equity: 0.027547314558876483
Current ratio: 3.4320065452140924
Quick ratio: 2.1122156782534143
Interest coverage ratio: 2.73661670235546
COGS to revenue (%): 68.4763920713733
R&D to revenue (%): 11.630679919184134
SG&A to revenue (%): 17.674406000367345
Free cash flow (dilution-adjusted): 34463000
Buyback yield (%): 0
Retained earnings: 1714861000
Inventory turnover: 0.4828059851051724
Receivables turnover: 1.0988350356172722
Capitalized R&D asset: 38627000
ROCI (R&D-adjusted, %): 1.326224633222542
FCF margin (%): 10.37688979353413
Rule of 40 score: 10.37688979353413
Financial ratios for DIOD — quarterly report dated 2025-06-30
Total revenue: 366212000
Gross profit: 115324000
Operating income: 9476000
Net income: 46098000
Capital expenditures: 14876000
Operating cash flow: 41521000
Depreciation & amortization: 35884000
Net tangible assets: 1635483000
Owner earnings: 67106000
Return on net tangible assets (%): 4.103130390227229
Capex to operating income (%): 156.98607007176025
Buffett classification: The Gruesome
Stock price: 52.89
P/E ratio: 56.106231240562444
Shares outstanding: 45944734
Book value: 1934171000
P/B ratio: 1.256360984245964
Market cap (USD): 2430016981.26
Debt to equity: 0.027907563498780614
Current ratio: 3.3311136864249145
Quick ratio: 2.039201569454518
Effective tax rate (%): 17.02835240403585
Interest coverage ratio: 18.727272727272727
COGS to revenue (%): 68.50895109936322
R&D to revenue (%): 11.06927135102072
SG&A to revenue (%): 16.239227551254466
Free cash flow (dilution-adjusted): 15284000
Buyback yield (%): 0
Retained earnings: 1760959000
Inventory turnover: 0.5197586083310373
Receivables turnover: 1.1681701606420578
Capitalized R&D asset: 66417090
ROCI (R&D-adjusted, %): 1.0915572383807937
Rosenberg metric: 0.27519610635048025
FCF margin (%): 4.173538824506024
Revenue growth (%): 10.26728854335723
Rule of 40 score: 14.440827367863253
Financial ratios for DIOD — quarterly report dated 2025-09-30
Total revenue: 392170000
Gross profit: 120488000
Operating income: 12280000
Net income: 15477000
Capital expenditures: 16288000
Operating cash flow: 79133000
Depreciation & amortization: 36699000
Net tangible assets: 1655746000
Owner earnings: 35888000
Return on net tangible assets (%): 2.1674822104356584
Capex to operating income (%): 132.6384364820847
Buffett classification: The Gruesome
Stock price: 53.21
P/E ratio: 41.5853455831122
Shares outstanding: 45944734
Book value: 1947421000
P/B ratio: 1.255362500527621
Market cap (USD): 2444719296.14
Debt to equity: 0.02979427663561192
Current ratio: 3.3181950828044067
Quick ratio: 2.091209913599933
Effective tax rate (%): 18.67906683480454
Interest coverage ratio: 24.41351888667992
COGS to revenue (%): 69.27658923426065
R&D to revenue (%): 10.674197414386619
SG&A to revenue (%): 15.426473213147359
Free cash flow (dilution-adjusted): 55985000
Buyback yield (%): 0
Retained earnings: 1775237000
Inventory turnover: 0.5769273240010873
Receivables turnover: 1.2908269231402212
Capitalized R&D asset: 81767700
ROCI (R&D-adjusted, %): 0.6365702912654293
Rosenberg metric: 0.1273897920418383
FCF margin (%): 14.275696764158402
Revenue growth (%): 7.088243967974835
Rule of 40 score: 21.363940732133237
Financial ratios for DIOD — annual report dated 2025-12-31
Total revenue: 1482073000
Gross profit: 462436000
Operating income: 36428000
Net income: 69170000
Capital expenditures: 71371000
Operating cash flow: 215513000
Depreciation & amortization: 143747000
Net tangible assets: 1649229000
Owner earnings: 141546000
Return on net tangible assets (%): 8.582555848823906
Capex to operating income (%): 195.92346546612495
Buffett classification: The Gruesome
Stock price: 49.34
P/E ratio: 32.77306889634235
Shares outstanding: 45944734
Book value: 1938409000
P/B ratio: 1.169471032976013
Market cap (USD): 2266913175.56
Debt to equity: 0.049323439996409424
Current ratio: 3.322307976951948
Quick ratio: 2.075952846645874
Effective tax rate (%): 17.614549958908515
Interest coverage ratio: 13.122478386167147
COGS to revenue (%): 68.7980281673035
R&D to revenue (%): 10.942443455889151
SG&A to revenue (%): 16.301896060450463
Free cash flow (dilution-adjusted): 111406000
Buyback yield (%): 1.4916318968258175
Retained earnings: 1785439000
Inventory turnover: 2.1623277474519984
Receivables turnover: 4.826734624090147
Capitalized R&D asset: 296495610
ROCI (R&D-adjusted, %): 2.3203325865543323
Rosenberg metric: 0.19823798405084633
FCF margin (%): 7.516903688279862
Revenue growth (%): 13.038699737628898
Rule of 40 score: 20.55560342590876
Financial ratios for DIOD — quarterly report dated 2025-12-31
Total revenue: 391578000
Gross profit: 121930000
Operating income: 13128000
Net income: 12320000
Capital expenditures: 24371000
Operating cash flow: 38116000
Depreciation & amortization: 35260000
Net tangible assets: 1649229000
Owner earnings: 23209000
Return on net tangible assets (%): 1.4072636365234905
Capex to operating income (%): 185.6413772090189
Buffett classification: The Gruesome
Stock price: 49.34
P/E ratio: 31.879861275243293
Shares outstanding: 45944734
Book value: 1938409000
P/B ratio: 1.169471032976013
Market cap (USD): 2266913175.56
Debt to equity: 0.049323439996409424
Current ratio: 3.322307976951948
Quick ratio: 2.075952846645874
Effective tax rate (%): 14.864211180982656
Interest coverage ratio: 10.098461538461539
COGS to revenue (%): 68.86188703144713
R&D to revenue (%): 10.508761983563938
SG&A to revenue (%): 16.07317060713319
Free cash flow (dilution-adjusted): 5674000
Buyback yield (%): 1.0503269492938638
Retained earnings: 1785439000
Inventory turnover: 0.5718381663718916
Receivables turnover: 1.2752699027861458
Capitalized R&D asset: 82574080
ROCI (R&D-adjusted, %): 0.6084247540852643
Rosenberg metric: 0.03444733761735267
FCF margin (%): 1.449008882010736
Revenue growth (%): -0.15095494300940918
Rule of 40 score: 1.2980539390013268
Financial ratios for EKG.V — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.023622047244094488
Shares outstanding: 197582106
Market cap (USD): 4667293.842519685
Buyback yield (%): 0
Capitalized R&D asset: 8774.8031496063
Rule of 40 score: 0
Financial ratios for EKG.V — annual report dated 2022-12-31
Total revenue: 732216.1764705882
Gross profit: 544400.7352941176
Operating income: -54230.882352941175
Net income: -1805.1470588235293
Capital expenditures: 7491.176470588235
Operating cash flow: 40085.294117647056
Depreciation & amortization: 21121.323529411762
Net tangible assets: -299502.94117647054
Owner earnings: 11825
Buffett classification: The Gruesome
Stock price: 0.022058823529411763
Shares outstanding: 197582106
Book value: -299502.9411764706
Market cap (USD): 4358428.808823529
Debt to equity: -0.8460979465977942
Current ratio: 0.35736658865173904
Quick ratio: 0.2983037575249473
Interest coverage ratio: -2.9841796479870526
COGS to revenue (%): 25.650272038754224
R&D to revenue (%): 0
SG&A to revenue (%): 62.66160146372716
Free cash flow (dilution-adjusted): 28159.55882352941
Buyback yield (%): 0
Retained earnings: -25848750
Inventory turnover: 6.294610512826832
Receivables turnover: 7.370885485673681
Capitalized R&D asset: 5879.118110236221
FCF margin (%): 3.845798512573633
Rule of 40 score: 3.845798512573633
Financial ratios for EKG.V — annual report dated 2023-12-31
Total revenue: 663950
Gross profit: 567191.6666666666
Operating income: -156084.0909090909
Net income: -73731.81818181818
Capital expenditures: 1533.3333333333333
Operating cash flow: -40959.84848484848
Depreciation & amortization: 18515.151515151516
Net tangible assets: -382310.606060606
Owner earnings: -56749.99999999999
Buffett classification: The Gruesome
Stock price: 0.007575757575757576
Shares outstanding: 197582106
Book value: -382310.6060606061
Market cap (USD): 1496834.1363636365
Debt to equity: -0.9695868423659961
Current ratio: 0.3234446646301236
Quick ratio: 0.27073246434688414
Interest coverage ratio: -7.186292291594001
COGS to revenue (%): 14.573135527273639
SG&A to revenue (%): 92.40781183322036
Free cash flow (dilution-adjusted): -42493.181818181816
Buyback yield (%): 0
Retained earnings: -26705777.27272727
Inventory turnover: 3.044745875846286
Receivables turnover: 8.233878241262683
Capitalized R&D asset: 2895.685039370079
FCF margin (%): -6.400057507068577
Revenue growth (%): -9.323227028340629
Rule of 40 score: -15.723284535409206
Financial ratios for EKG.V — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.014814814814814814
Shares outstanding: 197582106
Market cap (USD): 2927142.3111111107
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for EKG.V — annual report dated 2024-12-31
Total revenue: 368304.8951048951
Gross profit: 355127.27272727276
Operating income: -182632.16783216785
Net income: -136067.13286713287
Capital expenditures: 3499.3006993006993
Operating cash flow: -77384.61538461539
Depreciation & amortization: 20270.629370629373
Net tangible assets: -193411.18881118883
Owner earnings: -119295.80419580419
Buffett classification: The Gruesome
Stock price: 0.006993006993006994
Shares outstanding: 197582106
Book value: -193411.18881118885
Market cap (USD): 1381693.048951049
Debt to equity: -1.0190759930290911
Current ratio: 0.3370800179192355
Quick ratio: 0.2790792926168484
Interest coverage ratio: -6.885420511468495
COGS to revenue (%): 3.577911277521664
SG&A to revenue (%): 121.1691818119679
Free cash flow (dilution-adjusted): -83369.23076923078
Buyback yield (%): 0
Retained earnings: -24787553.846153848
Inventory turnover: 0.6930744050902938
Receivables turnover: 12.836050790865443
Capitalized R&D asset: 0
FCF margin (%): -22.63592797089672
Revenue growth (%): -44.52821822352661
Rule of 40 score: -67.16414619442332
Financial ratios for EKG.V — quarterly report dated 2024-12-31
Total revenue: 119154.54545454546
Gross profit: 108927.97202797203
Operating income: -12769.930069930071
Net income: -64806.99300699301
Capital expenditures: 0
Operating cash flow: -32169.23076923077
Depreciation & amortization: 5501.398601398601
Net tangible assets: -193411.18881118883
Owner earnings: -59305.59440559441
Buffett classification: The Gruesome
Stock price: 0.006993006993006994
Shares outstanding: 197582106
Book value: -193411.18881118885
Market cap (USD): 1381693.048951049
Debt to equity: -1.0190759930290911
Current ratio: 0.3370800179192355
Quick ratio: 0.2790792926168484
COGS to revenue (%): 8.582612931434172
SG&A to revenue (%): 113.94146404446246
Free cash flow (dilution-adjusted): -35645.45454545455
Buyback yield (%): 0
Retained earnings: -24787553.846153848
Inventory turnover: 0.537864577586524
Receivables turnover: 4.152738173576076
Capitalized R&D asset: 0
FCF margin (%): -29.91531242847334
Rule of 40 score: -29.91531242847334
Financial ratios for EKG.V — quarterly report dated 2025-03-31
Total revenue: 69958.74125874125
Gross profit: 65491.608391608395
Operating income: -59974.12587412588
Net income: -12666.433566433567
Capital expenditures: 0
Operating cash flow: -68413.28671328671
Depreciation & amortization: 4940.559440559441
Net tangible assets: -206077.62237762238
Owner earnings: -7725.874125874126
Buffett classification: The Gruesome
Stock price: 0.006993006993006994
Shares outstanding: 197582106
Book value: -206077.62237762238
Market cap (USD): 1381693.048951049
Debt to equity: -1.2078142868292552
Current ratio: 0.3733851091166998
Quick ratio: 0.32342491461386763
Interest coverage ratio: -14.42849932705249
COGS to revenue (%): 6.385381993382714
SG&A to revenue (%): 152.4444977559201
Free cash flow (dilution-adjusted): -68413.28671328671
Buyback yield (%): 0
Retained earnings: -24800220.27972028
Inventory turnover: 0.2441056211548015
Receivables turnover: 1.1278706637053404
Capitalized R&D asset: 0
FCF margin (%): -97.79090572865125
Revenue growth (%): -41.28739193971513
Rule of 40 score: -139.0782976683664
Financial ratios for EKG.V — quarterly report dated 2025-06-30
Total revenue: 52578.10218978102
Gross profit: 40279.56204379562
Operating income: -108143.79562043794
Net income: -90702.1897810219
Capital expenditures: 0
Operating cash flow: -130618.97810218977
Depreciation & amortization: 5156.204379562043
Net tangible assets: -305805.10948905104
Owner earnings: -85545.98540145985
Buffett classification: The Gruesome
Stock price: 0.0072992700729927005
Shares outstanding: 197582106
Book value: -305805.10948905104
Market cap (USD): 1442205.1532846715
Debt to equity: -1.298212448651758
Current ratio: 0.27979781561829725
Quick ratio: 0.23685435011935377
Interest coverage ratio: -17.741228595377798
COGS to revenue (%): 23.390992892047976
SG&A to revenue (%): 222.5177698800533
Free cash flow (dilution-adjusted): -130618.97810218977
Buyback yield (%): 0
Retained earnings: -25977063.503649633
Inventory turnover: 0.6252180043786411
Receivables turnover: 1.0387932277696057
Capitalized R&D asset: 0
FCF margin (%): -248.42847623278539
Revenue growth (%): -24.844127776224884
Rule of 40 score: -273.27260400901025
Financial ratios for EKG.V — quarterly report dated 2025-09-30
Total revenue: 31707.91366906475
Gross profit: 29805.035971223024
Operating income: -124651.79856115108
Net income: -122142.44604316547
Capital expenditures: 0
Operating cash flow: -87664.02877697842
Depreciation & amortization: 5082.014388489209
Net tangible assets: -408443.8848920864
Owner earnings: -117060.43165467627
Buffett classification: The Gruesome
Stock price: 0.007194244604316547
Shares outstanding: 197582106
Book value: -408443.88489208627
Market cap (USD): 1421454
Debt to equity: -1.133847186285199
Current ratio: 0.26532005815234155
Quick ratio: 0.2343801244303469
Interest coverage ratio: -12.99235152969406
COGS to revenue (%): 6.00127059037074
SG&A to revenue (%): 416.27943912510784
Free cash flow (dilution-adjusted): -87664.02877697842
Buyback yield (%): 0
Retained earnings: -25740277.69784173
Inventory turnover: 0.10461574971324605
Receivables turnover: 0.29533880132947354
Capitalized R&D asset: 0
FCF margin (%): -276.4736579389209
Revenue growth (%): -39.69368929556488
Rule of 40 score: -316.16734723448576
Financial ratios for ENX.PA — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 91.27272727272727
Shares outstanding: 99740109
Market cap (USD): 9103551766.90909
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ENX.PA — annual report dated 2022-12-31
Total revenue: 1504107446.8085108
Gross profit: 1103811702.1276596
Operating income: 665168085.106383
Net income: 479404255.31914896
Capital expenditures: 33844680.85106383
Operating cash flow: 655836170.212766
Depreciation & amortization: 170415957.44680852
Net tangible assets: -2438147872.3404255
Owner earnings: 615975531.9148936
Return on net tangible assets (%): -25.264076018638143
Capex to operating income (%): 5.088139615966529
Buffett classification: The Great
Stock price: 66.38297872340426
P/E ratio: 13.810986156577314
Shares outstanding: 99740109
Book value: 4298197872.340424
P/B ratio: 1.5404236217751832
Market cap (USD): 6621045533.6170225
Debt to equity: 0.7659432231123092
Current ratio: 1.0059843919015488
Quick ratio: 1.0059843919015488
Effective tax rate (%): 26.63513744515625
Interest coverage ratio: 16.75396570203644
COGS to revenue (%): 26.61350726839484
SG&A to revenue (%): 5.038189751326332
Free cash flow (dilution-adjusted): 535079787.23404264
Buyback yield (%): 0.0002892131774806246
Retained earnings: 1346558510.638298
Receivables turnover: 5.20128830993014
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 8.086465944677258
FCF margin (%): 35.57457204067444
Rule of 40 score: 35.57457204067444
Financial ratios for ENX.PA — annual report dated 2023-12-31
Total revenue: 1637262222.222222
Gross profit: 1224806666.6666667
Operating income: 684707777.7777778
Net income: 596016666.6666666
Capital expenditures: 30781111.111111112
Operating cash flow: 917858888.8888888
Depreciation & amortization: 189034444.44444445
Net tangible assets: -2402734444.444444
Owner earnings: 754269999.9999999
Return on net tangible assets (%): -31.392149962473308
Capex to operating income (%): 4.495510655802882
Buffett classification: The Great
Stock price: 81.53333333333333
P/E ratio: 13.644154616146082
Shares outstanding: 99740109
Book value: 4539273333.3333435
P/B ratio: 1.7915077935675419
Market cap (USD): 8132143553.8
Debt to equity: 0.760862849805131
Current ratio: 1.0065929289641549
Quick ratio: 1.0065929289641549
Effective tax rate (%): 23.271950703177747
Interest coverage ratio: 17.254774038192306
COGS to revenue (%): 25.191783573662264
SG&A to revenue (%): 5.189489771542738
Free cash flow (dilution-adjusted): 787398888.8888888
Buyback yield (%): 2.993074452029001
Retained earnings: 1714953333.3333333
Receivables turnover: 5.603331115125012
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.924670002063978
FCF margin (%): 48.09241172255038
Revenue growth (%): 8.852743578674891
Rule of 40 score: 56.94515530122527
Financial ratios for ENX.PA — quarterly report dated 2024-12-31
Operating income: 240416666.6666667
Net income: 159270833.33333334
Capital expenditures: 7662500
Operating cash flow: 182388541.6666667
Depreciation & amortization: 51681250
Net tangible assets: -1928184375
Owner earnings: 203289583.33333334
Return on net tangible assets (%): -10.543057291050467
Capex to operating income (%): 3.1871750433275556
Buffett classification: The Great
Stock price: 108.22916666666667
P/E ratio: 16.944076725147156
Shares outstanding: 99740109
Book value: 4585395833.333313
P/B ratio: 2.3541672895151833
Market cap (USD): 10794788880.3125
Debt to equity: 0.7077558280591947
Current ratio: 1.0033830083564792
Quick ratio: 1.0033830083564792
Effective tax rate (%): 26.63147792706334
Free cash flow (dilution-adjusted): 145061458.33333334
Buyback yield (%): 0
Retained earnings: 1916586458.3333335
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.0488163314047583
Rule of 40 score: 0
Financial ratios for ENX.PA — annual report dated 2024-12-31
Total revenue: 1693056250
Gross profit: 1311183333.3333335
Operating income: 819632291.6666667
Net income: 646545833.3333334
Capital expenditures: 18712500
Operating cash flow: 738122916.6666667
Depreciation & amortization: 196609375
Net tangible assets: -1928184375
Owner earnings: 824442708.3333334
Return on net tangible assets (%): -42.7574623579933
Capex to operating income (%): 2.2830359650605514
Buffett classification: The Great
Stock price: 108.22916666666667
P/E ratio: 16.696092254834987
Shares outstanding: 99740109
Book value: 4585395833.333313
P/B ratio: 2.3541672895151833
Market cap (USD): 10794788880.3125
Debt to equity: 0.7077558280591947
Current ratio: 1.0033830083564792
Quick ratio: 1.0033830083564792
Effective tax rate (%): 26.0261793270795
Interest coverage ratio: 21.549776791827572
COGS to revenue (%): 22.555240953551703
SG&A to revenue (%): 4.342922746955395
Free cash flow (dilution-adjusted): 631044791.6666666
Buyback yield (%): 1.0292292534097587
Retained earnings: 1916586458.3333335
Receivables turnover: 5.499874797815391
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 10.394072720610223
FCF margin (%): 37.27252367821014
Revenue growth (%): 3.4077637058069925
Rule of 40 score: 40.680287384017134
Financial ratios for ENX.PA — quarterly report dated 2025-03-31
Total revenue: 498369565.2173913
Gross profit: 375000000
Operating income: 267500000
Net income: 191956521.73913044
Capital expenditures: 7391304.347826087
Operating cash flow: 207173913.04347825
Depreciation & amortization: 52500000
Net tangible assets: -2034673913.0434783
Owner earnings: 237065217.39130434
Return on net tangible assets (%): -11.651263422191356
Capex to operating income (%): 2.7631044290938642
Buffett classification: The Great
Stock price: 139.42391304347828
P/E ratio: 18.111075568275766
Shares outstanding: 99740109
Book value: 4767717391.304382
P/B ratio: 2.9167325038027285
Market cap (USD): 13906156284.163046
Debt to equity: 0.7193078448806459
Current ratio: 1.0026118847167724
Quick ratio: 1.0026118847167724
Effective tax rate (%): 27.74140752864157
COGS to revenue (%): 24.7546346782988
SG&A to revenue (%): 3.729552889858233
Free cash flow (dilution-adjusted): 170543478.26086956
Buyback yield (%): 1.5984475088116012
Receivables turnover: 0.7985022640195055
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.247387311305811
FCF margin (%): 34.220283533260634
Rule of 40 score: 34.220283533260634
Financial ratios for ENX.PA — quarterly report dated 2025-06-30
Total revenue: 547517647.0588236
Gross profit: 479535294.11764705
Operating income: 288896470.5882353
Net income: 231123529.4117647
Capital expenditures: 3808235.294117647
Operating cash flow: 158754117.6470588
Depreciation & amortization: 56663529.4117647
Net tangible assets: -2862521176.470588
Owner earnings: 283978823.5294118
Return on net tangible assets (%): -9.920584199120233
Capex to operating income (%): 1.3182006988051898
Buffett classification: The Great
Stock price: 167.0705882352941
P/E ratio: 18.024602172367715
Shares outstanding: 99740109
Book value: 5056322352.941223
P/B ratio: 3.2956044963369955
Market cap (USD): 16663638681.282352
Debt to equity: 0.6995165516718201
Current ratio: 1.0001334393994066
Quick ratio: 1.0001334393994066
Effective tax rate (%): 25.73909362041527
COGS to revenue (%): 12.416467908635767
SG&A to revenue (%): 4.263306044392874
Free cash flow (dilution-adjusted): 115270588.23529413
Buyback yield (%): 0
Retained earnings: 2218605882.352941
Receivables turnover: 1.1218433917327961
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.385705918622385
FCF margin (%): 21.053310126990265
Revenue growth (%): 9.86177432805184
Rule of 40 score: 30.915084455042106
Financial ratios for ENX.PA — quarterly report dated 2025-09-30
Total revenue: 515294117.64705884
Gross profit: 384117647.0588235
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 146.69411764705882
P/E ratio: 25.124521441630474
Shares outstanding: 99740109
Market cap (USD): 14631287283.77647
COGS to revenue (%): 25.456621004566216
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -5.885386450074137
Rule of 40 score: -5.885386450074137